Health Care - As enacted, enacts the "Individualized Investigational Treatment Act." - Amends TCA Title 53 and Title 63.

HB 192, enacted as the "Individualized Investigational Treatment Act," allows patients with life-threatening or severely debilitating illnesses (after exhausting all FDA-approved treatments) to access custom-made therapies like personalized gene therapies or vaccines. It requires detailed written consent from patients and physicians outlining risks, outcomes, and financial responsibilities, while clarifying that insurers, hospitals, and manufacturers are not obligated to cover or provide these treatments. The law permits manufacturers to supply such therapies without compensation but allows them to charge patients for manufacturing costs. It also protects patients’ heirs from liability for treatment debts if the patient dies during treatment.